Biofilm formation can cause refractory urinary tract infections (UTIs) in dogs; however, minimum biofilm eradication concentrations (MBECs) of veterinary drugs against canine uropathogens remain to be investigated. In this study, the MBECs of orbifloxacin (OBFX), trimethoprim-sulfamethoxazole (TMS) and amoxicillin/clavulanate (ACV) over different time periods for treatment of canine uropathogenic Escherichia coli (n ¼ 10) were determined. The MBECs of OBFX for other bacterial uropathogens, including Staphylococcus pseudintermedius (n ¼ 5), Pseudomonas aeruginosa (n ¼ 5), Klebsiella pneumoniae (n ¼ 5) and Proteus mirabilis (n ¼ 5) were also determined. Minimum inhibitory concentrations (MICs) were identified for all strains by broth microdilution, and MBECs were determined at 24, 72, and 168 hr using the Calgary biofilm method. The 24 hr MBECs of OBFX, TMS and ACV for the E. coli strains were significantly higher than the MICs (P < 0.05), and the 72 and 168 hr MBECs were significantly lower than those at 24 hr (P < 0.05). In addition, the 24 hr OBFX MBECs for the four other uropathogens were significantly higher than the corresponding MICs (P < 0.05). The 72 and/or 168 hr OBFX MBECs for S. pseudintermedius, K. pneumoniae and P. mirabilis were significantly lower than the 24 hr concentrations (P < 0.05), whereas for P. aeruginosa, no significant difference was found between any of the MBECs (P > 0.05). These data indicate that the administration period and uropathogenic bacterial species are important factors affecting the efficacy of OBFX treatment of biofilm-related UTIs in dogs.
Urinary tract infections are common in dogs, approximately 14% contracting a UTI at some point in their lifetimes (1) . Antimicrobial therapy is required for UTIs in dogs (2, 3) ; however, these infections occasionally do not respond to treatment. As is also true in humans, biofilm formation, defined as communities of bacteria encased in an extracellular matrix (4) , can cause refractory UTIs in dogs (1, 5) because the causative organisms are shielded from both antimicrobials and the host immune response (6) . Potentiated sulfonamides and b-lactams are recommended as representative antimicrobial options for treatment of canine UTIs (1, 2) . Notably, second-line drugs such as fluoroquinolones are considered for cases of refractory UTI, including biofilm-related UTIs (1, 2) .
To select antimicrobials that effectively eliminate bacterial biofilms, the susceptibility of biofilms to various antimicrobial drugs must be measured (7) . The Calgary biofilm method is a newly developed assay for rapid and reproducible determination of the minimum biofilm eradication concentration (MBEC) of a drug (8) . In general, MBECs are determined following 24 hr of exposure to the antimicrobials, as previously reported (8) (9) (10) . However, MBECs for extended exposure to antimicrobials need to be investigated to estimate clinical efficacy against canine biofilm-related UTIs because several guidelines recommend at least a 7-day course of antibiotic treatment for this type of infection (2, 3) .
Escherichia coli is the most common bacterial pathogen associated with UTIs in dogs, followed by Staphylococcus, Proteus, Klebsiella, and Pseudomonas species (11) (12) (13) (14) . Previous in vitro studies have demonstrated that almost all clinical E. coli and Staphylococcus pseudintermedius isolates from dogs can produce biofilms (5, 15) . Likewise, most Proteus mirabilis, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolates from human patients have been identified as biofilm producers (16) (17) (18) . It is likely that these bacteria can induce biofilm-related UTIs in dogs; however, MBECs of veterinary antimicrobials against these pathogens remain to be investigated.
Therefore, the aim of this study was to investigate the MBECs of veterinary OBFX (19) , TMS and ACV against uropathogenic E. coli over several different treatment periods. Further, we aimed to compare the MBECs of OBFX for common UTI pathogens of dogs.
MATERIALS AND METHODS

Tested strains
Thirty bacterial strains were used in this study, including 10 E. coli, five S. pseudintermedius, five P. aeruginosa, five K. pneumoniae and five P. mirabilis strains. S. pseudintermedius strains obtained from different dogs with UTIs were kindly provided by Mr. Y. Tsuyuki (Sanritsu Zelkova Veterinary Laboratory, Kanagawa, Japan). Several other strains were randomly selected from our collection (20) (21) (22) (23) on the basis of the following criteria: i) isolates obtained from different dogs with UTIs, and ii) fluoroquinolone-susceptible isolates (in the case of E. coli, isolates susceptible to TMS and ACV, in addition to fluoroquinolones).
Determination of MICs
The MICs of OBFX, TMS and ACV for E. coli were determined using a broth microdilution method, according to the guidelines of the Clinical and Laboratory Standards Institute (24) . The MIC of OBFX was also determined for all other bacteria using the same method.
MBEC determination
The MBECs of OBFX, TMS and ACV were determined for E. coli according to a previously described protocol (25) , whereas the MBEC of OBFX was determined for all other species. Briefly, a 1.0 McFarland standard suspension of each strain was prepared in tryptic soy broth and then diluted 30-fold in tryptic soy broth. An aliquot (150 mL) of each dilution was dispensed into an individual well of a 96-well plate, after which a peg lid (Immuno TSP; Nunc, Roskilde, Denmark) was placed into each well. The plates wereincubated for 24 hr at 37°C with shaking (150 rpm) to allow bacterial biofilms to grow on the pegs. Following incubation, several pegs were removed from the lid and the number of bacteria within biofilms on them determined by 10-fold serial dilutions (i.e. 10 6 -10 7 CFU/peg). The remaining pegs were dipped for 1 min into the wells of a 96-well plate containing 200 mL of 0.85% saline solution (rinse plate) to remove any loosely adherent planktonic cells from the biofilms. The peg lids were then transferred into the wells of a 96-well plate, each containing 200 mL of MuellerHinton broth supplemented with two-fold-diluted antimicrobial solution (challenge plate). The plates were then incubated at 37°C for 24, 72 or 168 hr. During the incubation period, challenge plates were freshly prepared every 24 hr. Following challenge, the peg lids were washed twice in fresh rinse plates for 1 min each wash, and then placed into a 96-well plate containing 200 mL of Mueller-Hinton Broth per well (recovery plate). The pegs were then sonicated for 1 hr to disrupt the biofilms and the peg lids discarded. The original microtiter plate lids were replaced, and the plates incubated at 37°C for 24 hr. Following incubation, the lowest concentration of antimicrobial that prevented visible growth of the bacterium was deemed to be the MBEC. Each experiment was performed three times; the results are shown as median values.
Statistical analysis
The Wilcoxon matched-pairs signed-rank test was used to compare MICs and MBECs, as well as the 24 hr MBECs with the 72 or 168 hr MBECs for each drug and bacterial species. P < 0.05 was considered to denote significance for all analyses.
RESULTS
OBFX, TMS, and ACV MBECs for canine uropathogenic E. coli
The MICs and MBECs determined following 24, 72, or 168 hr exposure of the 10 E. coli strains to the three tested drugs are presented in Table 1 . For OBFX, TMS, and ACV, the 24 hr MBECs (medians: 64-2048, 16/304-> 256/4864, and >512/256 mg/mL, respectively) were significantly higher than the MICs (P < 0.05), while the 72 hr MBECs (medians: 0.25-64, 4/76-256/4864, and 8/4-128/64 mg/mL, respectively) and 168 hr MBECs (medians: 0.25-2, 0.25/4.75-2/38, and 4/2-512/ 256 mg/mL, respectively) were significantly lower than the 24 hr MBECs (P < 0.05).
The median MBECs of OBFX, TMS, and ACV were assessed according to the CLSI guidelines on susceptibility breakpoints for canine UTIs (1, 2/38, and 8/4 mg/mL, respectively) (27) . Most of E. coli strains had susceptible MBECs for all three drugs after 72 and/or 168 hr exposure, with the exception of several strains. For example, after both 72 and 168 hr exposure, the EC1 and EC2 strains had non-susceptible MBECs for ACV and the EC9 strain had non-susceptible MBECs for OBFX. After 72 hr exposure, the majority (8/10) of the strains had MBECs classed as susceptible for OBFX, whereas 0/10 and 3/10 of the strains had susceptible MBECs for TMS and ACV, respectively. After 168 hr exposure, most or all of the strains had susceptible MBECs for all three drugs.
OBFX MBECs for other canine uropathogenic bacteria
The MIC and MBEC values of OBFX for the four non-E. coli bacterial species (S. pseudintermedius, P. aeruginosa, K. pneumoniae and P. mirabilis) are presented in Table 2 . Like E. coli, the 24 hr OBFX median MBECs were significantly higher than the MICs (P < 0.05) for each bacterial species. In the three species other than P. aeruginosa, all strains had low OBFX median MBECs (4 mg/mL) after 168 hr exposure, whereas betweenstrain variations were observed in OBFX median MBECs after 72 hr exposure: SP5 strain had a relatively high concentration (128 mg/mL) in S. pseudintermedius, whereas KP3 and PM4 strains had relatively low concentrations (1 and 4 mg/mL, respectively) in K. pneumoniae and P. mirabilis, respectively. The 72 and 168 hr OBFX median MBECs for S. pseudintermedius and K. pneumoniae and the 168 hr MBEC for P. mirabilis were significantly lower than the 24 hr MBECs (P < 0.05). In P. aeruginosa, no significant difference was observed between 24 hr MBECs (medians: 32->2048 mg/mL) and 72 hr MBECs (medians: 2048->2048 mg/mL) or 168 hr MBECs (medians: 64->2048 mg/mL; P > 0.05).
DISCUSSION
To estimate the clinical efficacy of OBFX, a second-line drug for the treatment of canine UTIs, we investigated the MBECs of OBFX and other major first-line drugs (TMS and ACV) for uropathogenic canine E. coli strains. We determined that the 24 hr MBECs of all three drugs were significantly higher than the respective MICs, as previously reported for other veterinary pathogens (25, 26) . Antunes et al. (9) have reported that all strong, moderate and weak biofilm-producing isolates have higher 24 hr MBECs than MICs, whereas the MICs and MBECs of non-biofilm producers were identical in their study. These findings imply that all E. coli strains used in this study are biofilm producers and that the demonstrated resistance to the tested drugs was attributable to biofilm formation. Therefore, 24 hr of treatment with either the first-or second-line drugs tested is unlikely to eradicate biofilm-forming E. coli uropathogens.
The present data also demonstrate that 72 and 168 hr challenge with the tested drugs significantly decreases the MBECs, indicating that longer courses of antibiotics should be used to eradicate biofilm-forming E. coli strains. When compared with CLSI susceptibility breakpoints for canine UTIs (27) , the 168 hr MBECs of all three drugs were classed as susceptible for the majority of the E. coli strains tested. In contrast, most of the isolates had susceptible MBECs for OBFX after 72 hr, but had resistant MBECs for both TMS and ACV. These data suggest that a 3-day course of OBFX, as well as the standard 7-day course, may be sufficient to eradicate biofilm-forming E. coli strains. Shorter courses of antibiotics are also preferable in regard to development of resistance (28) . Further clinical trials are needed to determine the appropriate duration of OBFX treatment for biofilm-related UTIs in dogs.
In this study, we also investigated the MBECs of OBFX for several other canine uropathogens over different treatment periods. Like E. coli, all S. pseudintermedius, K. pneumoniae, P. mirabilis and P. aeruginosa strains tested had high 24 hr MBECs for OBFX, implying that all strains are biofilm producers. Exposure to OBFX for 72 and/or 168 hr induced a decrease in the MBECs for S. pseudintermedius, K. pneumoniae and P. mirabilis, whereas the OBFX MBECs for P. aeruginosa were consistently extremely high for at least 168 hr. In this study, we found that the number of bacteria within biofilm were mostly the same for the various tested bacterial species; thus, it is likely that between-species differences in MBECs are independent of the quantity of biofilm. P. aeruginosa has a remarkable ability to form biofilms, which renders most antimicrobial treatments ineffective (29) . This trait explains our findings, which imply that administration of OBFX alone will have negligible effects on biofilm-forming strains of P. aeruginosa. In recent years, several studies have identified anti-biofilm effects associated with some antimicrobials (e.g., azithromycin) and other substances (e.g., N-acetylcysteine, cranberry proanthocyanidin and lactoferrin) (30) (31) (32) (33) . Further studies are required to establish the efficacy of combination therapies with OBFX and antibiofilm agents against canine UTIs caused by biofilm-forming strains of P. aeruginosa.
In conclusion, we investigated the MBECs of OBFX, TMS and ACV for canine uropathogenic E. coli strains over various treatment periods and compared OBFX MBECs among common bacterial species from dogs with UTIs. Our data suggest that OBFX is likely to eradicate biofilm-forming E. coli more quickly than TMS and ACV; however, these three drugs have similar efficacy over a longer treatment period. We also found clear differences in OBFX MBECs between the pathogens. In particular, 72 and/or 168 hr exposure to OBFX can eradicate biofilm-forming isolates of E. coli, S. pseudintermedius, K. pneumoniae and P. mirabilis, but not of P. aeruginosa. These data indicate that the duration of administration and uropathogenic bacterial species are important factors affecting the MBECs of OBFX, and thus should be considered in the treatment of biofilm-related UTIs in dogs.
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